Our team is focused on developing and delivering the first oral drug for eosinophilic asthma
Our global development team brings together experts from Knopp Biosciences, which previously developed dexpramipexole, and Population Health Partners,
whose employees and executives led eight drug approvals involving 21 clinical trials and 91,000 patients worldwide in their earlier work at The Medicines Company.
Our global development team brings together experts from Knopp Biosciences, which previously developed dexpramipexole, and Population Health Partners, whose employees and executives led eight drug approvals involving 21 clinical trials and 91,000 patients worldwide in their earlier work at The Medicines Company.
Company Leaders
Jorge Bartolome
Chief Executive Officer
Peter Wijngaard, Ph.D.
Chief Development Officer
Calman Prussin, M.D.
Chief Scientific Officer
Mark Kreston
Chief Commercial Officer
Christopher Courts, CPA
Chief Financial Officer
Eric Bradford, M.D.
Chief Medical Officer
Robin Walker, J.D.
Chief Legal Officer and Corporate Secretary
Andrew Friedman
PharmD – Executive Vice President, Head of Global Regulatory and Development Strategy
Dan Tokich
Head of Global Supply
Lex Kay
Head of Global Quality
Richard Fires
Head of Human Resources
Board of Directors
Jorge Bartolome
Chief Executive Officer, areteia therapeutics
Dan Becker, M.D., Ph.D.
Managing Director, Access Biotechnology
Paul Berns
Managing Director, Arch Venture Partners
Michael Bozik, M.D.
President, Biohaven Labs
Former Chief Executive Officer, Knopp Biosciences, LLC
Steve Butts
Chief Executive Officer, Arrivo BioVentures, LLC
Benjamin Gomez
Managing Director, Pilot House Associates
Don Hayden
Chair of the Board, areteia therapeutics
Adam Koppel, M.D., Ph.D.
Partner, Bain Capital
Ian Smith
Interim Chief Executive Officer, Stoke Therapeutics
Elyse Stock, M.D.
Senior Scientific Advisor, Biohaven Pharmaceuticals